Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTPS9579A in Refractory Chronic Spontaneous Urticaria
NCT05129423Phase 2Withdrawn
- Sponsor
- Genentech
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of MTPS9579A in chronic spontaneous urticaria (CSU) (8 arms), sponsored by Genentech. Primary endpoint: Change From Baseline in the Urticaria Activity Score over 7 days (UAS7) at 12 weeks. Planned start Jul 2022; status: withdrawn.
02
Drugs
MTPS9579A
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT05129423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05129423.